Consequences of intratracheal administration of surfactant and surfactant with budesonide
Not Applicable
- Conditions
- Respiratory Distress Syndrome.
- Registration Number
- IRCT20210412050944N1
- Lead Sponsor
- Qazvin University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Infants that have clinical signs of respiratory distress syndrome.
Infants that their ages are have 2 weeks.
Infants receiving nasal continuous positive airway pressure with surfactant.
Exclusion Criteria
Infants that have congenital anomalies.
Infants that have perinatal asphyxia.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of infants with respiratory distress syndrome. Timepoint: Before the intervention and every 12 hours after the administration of surfactant in the intervention group and surfactant with budosonide 0.25 mg intratracheally in the control group. Method of measurement: Mechanical Ventilation Device.
- Secondary Outcome Measures
Name Time Method Reduction of respiratory distress syndrome in preterm infants prescribed with surfactant and surfactant with budesonide. Timepoint: Before the intervention and every 12 hours after the administration of surfactant in the intervention group and surfactant with budosonide 0.25 mg intratracheally in the control group. Method of measurement: Mechanical Ventilation Devices.